

Global Tyrosine Kinase JAK Inhibitors Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030

<https://marketpublishers.com/r/G5C2415C9E99EN.html>

Date: April 2024

Pages: 195

Price: US\$ 4,250.00 (Single User License)

ID: G5C2415C9E99EN

Abstracts

Summary

Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.

These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.

In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.

According to APO Research, The global Tyrosine Kinase JAK Inhibitors market is projected to grow from US\$ million in 2024 to US\$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

North American market for Tyrosine Kinase JAK Inhibitors is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Tyrosine Kinase JAK Inhibitors is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of

2025 through 2030.

The China market for Tyrosine Kinase JAK Inhibitors is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Tyrosine Kinase JAK Inhibitors is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Tyrosine Kinase JAK Inhibitors include Pfizer, Incyte, Novartis, Eli Lilly, Gilead, Sanofi, Galapagos, AbbVie and Vertex, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Tyrosine Kinase JAK Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Tyrosine Kinase JAK Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for Tyrosine Kinase JAK Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Tyrosine Kinase JAK Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Tyrosine Kinase JAK Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Tyrosine Kinase JAK Inhibitors sales, projected growth trends, production technology, application and end-user industry.

Tyrosine Kinase JAK Inhibitors segment by Company

Pfizer

Incyte

Novartis

Eli Lilly

Gilead

Sanofi

Galapagos

AbbVie

Vertex

Teva

Astellas Pharma

Celgene

CTI BioPharma

Tyrosine Kinase JAK Inhibitors segment by Type

Tofacitinib

Ruxolitinib

Baricitinib

Tyrosine Kinase JAK Inhibitors segment by Application

Rheumatoid Arthritis (RA)

Polycythemia Vera (PCV)

Myelofibrosis (MF)

Others

Tyrosine Kinase JAK Inhibitors segment by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Tyrosine Kinase JAK Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Tyrosine Kinase JAK Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Tyrosine Kinase JAK Inhibitors significant trends, drivers, influence factors in global and regions.
6. To analyze Tyrosine Kinase JAK Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tyrosine Kinase JAK Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tyrosine Kinase JAK Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tyrosine Kinase JAK Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tyrosine Kinase JAK Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2019-2030).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tyrosine Kinase JAK Inhibitors industry.

Chapter 3: Detailed analysis of Tyrosine Kinase JAK Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Tyrosine Kinase JAK Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Tyrosine Kinase JAK Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

Contents

1 MARKET OVERVIEW

- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
 - 1.2.1 Global Tyrosine Kinase JAK Inhibitors Sales Value (2019-2030)
 - 1.2.2 Global Tyrosine Kinase JAK Inhibitors Sales Volume (2019-2030)
 - 1.2.3 Global Tyrosine Kinase JAK Inhibitors Sales Average Price (2019-2030)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives

2 TYROSINE KINASE JAK INHIBITORS MARKET DYNAMICS

- 2.1 Tyrosine Kinase JAK Inhibitors Industry Trends
- 2.2 Tyrosine Kinase JAK Inhibitors Industry Drivers
- 2.3 Tyrosine Kinase JAK Inhibitors Industry Opportunities and Challenges
- 2.4 Tyrosine Kinase JAK Inhibitors Industry Restraints

3 TYROSINE KINASE JAK INHIBITORS MARKET BY COMPANY

- 3.1 Global Tyrosine Kinase JAK Inhibitors Company Revenue Ranking in 2023
- 3.2 Global Tyrosine Kinase JAK Inhibitors Revenue by Company (2019-2024)
- 3.3 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Company (2019-2024)
- 3.4 Global Tyrosine Kinase JAK Inhibitors Average Price by Company (2019-2024)
- 3.5 Global Tyrosine Kinase JAK Inhibitors Company Ranking, 2022 VS 2023 VS 2024
- 3.6 Global Tyrosine Kinase JAK Inhibitors Company Manufacturing Base & Headquarters
- 3.7 Global Tyrosine Kinase JAK Inhibitors Company, Product Type & Application
- 3.8 Global Tyrosine Kinase JAK Inhibitors Company Commercialization Time
- 3.9 Market Competitive Analysis
 - 3.9.1 Global Tyrosine Kinase JAK Inhibitors Market CR5 and HHI
 - 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
 - 3.9.3 2023 Tyrosine Kinase JAK Inhibitors Tier 1, Tier 2, and Tier
- 3.10 Mergers & Acquisitions, Expansion

4 TYROSINE KINASE JAK INHIBITORS MARKET BY TYPE

- 4.1 Tyrosine Kinase JAK Inhibitors Type Introduction

- 4.1.1 Tofacitinib
- 4.1.2 Ruxolitinib
- 4.1.3 Baricitinib
- 4.2 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Type
 - 4.2.1 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Type (2019 VS 2023 VS 2030)
 - 4.2.2 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Type (2019-2030)
 - 4.2.3 Global Tyrosine Kinase JAK Inhibitors Sales Volume Share by Type (2019-2030)
- 4.3 Global Tyrosine Kinase JAK Inhibitors Sales Value by Type
 - 4.3.1 Global Tyrosine Kinase JAK Inhibitors Sales Value by Type (2019 VS 2023 VS 2030)
 - 4.3.2 Global Tyrosine Kinase JAK Inhibitors Sales Value by Type (2019-2030)
 - 4.3.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type (2019-2030)

5 TYROSINE KINASE JAK INHIBITORS MARKET BY APPLICATION

- 5.1 Tyrosine Kinase JAK Inhibitors Application Introduction
 - 5.1.1 Rheumatoid Arthritis (RA)
 - 5.1.2 Polycythemia Vera (PCV)
 - 5.1.3 Myelofibrosis (MF)
 - 5.1.4 Others
- 5.2 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Application
 - 5.2.1 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Application (2019 VS 2023 VS 2030)
 - 5.2.2 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Application (2019-2030)
 - 5.2.3 Global Tyrosine Kinase JAK Inhibitors Sales Volume Share by Application (2019-2030)
- 5.3 Global Tyrosine Kinase JAK Inhibitors Sales Value by Application
 - 5.3.1 Global Tyrosine Kinase JAK Inhibitors Sales Value by Application (2019 VS 2023 VS 2030)
 - 5.3.2 Global Tyrosine Kinase JAK Inhibitors Sales Value by Application (2019-2030)
 - 5.3.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application (2019-2030)

6 TYROSINE KINASE JAK INHIBITORS MARKET BY REGION

- 6.1 Global Tyrosine Kinase JAK Inhibitors Sales by Region: 2019 VS 2023 VS 2030
- 6.2 Global Tyrosine Kinase JAK Inhibitors Sales by Region (2019-2030)
 - 6.2.1 Global Tyrosine Kinase JAK Inhibitors Sales by Region: 2019-2024

- 6.2.2 Global Tyrosine Kinase JAK Inhibitors Sales by Region (2025-2030)
- 6.3 Global Tyrosine Kinase JAK Inhibitors Sales Value by Region: 2019 VS 2023 VS 2030
- 6.4 Global Tyrosine Kinase JAK Inhibitors Sales Value by Region (2019-2030)
 - 6.4.1 Global Tyrosine Kinase JAK Inhibitors Sales Value by Region: 2019-2024
 - 6.4.2 Global Tyrosine Kinase JAK Inhibitors Sales Value by Region (2025-2030)
- 6.5 Global Tyrosine Kinase JAK Inhibitors Market Price Analysis by Region (2019-2024)
- 6.6 North America
 - 6.6.1 North America Tyrosine Kinase JAK Inhibitors Sales Value (2019-2030)
 - 6.6.2 North America Tyrosine Kinase JAK Inhibitors Sales Value Share by Country, 2023 VS 2030
- 6.7 Europe
 - 6.7.1 Europe Tyrosine Kinase JAK Inhibitors Sales Value (2019-2030)
 - 6.7.2 Europe Tyrosine Kinase JAK Inhibitors Sales Value Share by Country, 2023 VS 2030
- 6.8 Asia-Pacific
 - 6.8.1 Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Value (2019-2030)
 - 6.8.2 Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Value Share by Country, 2023 VS 2030
- 6.9 Latin America
 - 6.9.1 Latin America Tyrosine Kinase JAK Inhibitors Sales Value (2019-2030)
 - 6.9.2 Latin America Tyrosine Kinase JAK Inhibitors Sales Value Share by Country, 2023 VS 2030
- 6.10 Middle East & Africa
 - 6.10.1 Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Value (2019-2030)
 - 6.10.2 Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Value Share by Country, 2023 VS 2030

7 TYROSINE KINASE JAK INHIBITORS MARKET BY COUNTRY

- 7.1 Global Tyrosine Kinase JAK Inhibitors Sales by Country: 2019 VS 2023 VS 2030
- 7.2 Global Tyrosine Kinase JAK Inhibitors Sales Value by Country: 2019 VS 2023 VS 2030
- 7.3 Global Tyrosine Kinase JAK Inhibitors Sales by Country (2019-2030)
 - 7.3.1 Global Tyrosine Kinase JAK Inhibitors Sales by Country (2019-2024)
 - 7.3.2 Global Tyrosine Kinase JAK Inhibitors Sales by Country (2025-2030)
- 7.4 Global Tyrosine Kinase JAK Inhibitors Sales Value by Country (2019-2030)
 - 7.4.1 Global Tyrosine Kinase JAK Inhibitors Sales Value by Country (2019-2024)
 - 7.4.2 Global Tyrosine Kinase JAK Inhibitors Sales Value by Country (2025-2030)

7.5 USA

7.5.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.5.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.5.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.6 Canada

7.6.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.6.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.6.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.7 Germany

7.7.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.7.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.7.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.8 France

7.8.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.8.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.8.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.9 U.K.

7.9.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.9.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.9.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.10 Italy

7.10.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.10.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.10.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.11 Netherlands

7.11.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.11.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS

2030

7.11.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.12 Nordic Countries

7.12.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.12.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.12.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.13 China

7.13.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.13.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.13.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.14 Japan

7.14.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.14.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.14.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.15 South Korea

7.15.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.15.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.15.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.16 Southeast Asia

7.16.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.16.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.16.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.17 India

7.17.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.17.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.17.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.18 Australia

7.18.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.18.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.18.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.19 Mexico

7.19.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.19.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.19.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.20 Brazil

7.20.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.20.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.20.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.21 Turkey

7.21.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.21.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.21.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.22 Saudi Arabia

7.22.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.22.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.22.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

7.23 UAE

7.23.1 Global Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030)

7.23.2 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030

7.23.3 Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030

8 COMPANY PROFILES

8.1 Pfizer

8.1.1 Pfizer Company Information

8.1.2 Pfizer Business Overview

8.1.3 Pfizer Tyrosine Kinase JAK Inhibitors Sales, Value and Gross Margin
(2019-2024)

8.1.4 Pfizer Tyrosine Kinase JAK Inhibitors Product Portfolio

8.1.5 Pfizer Recent Developments

8.2 Incyte

8.2.1 Incyte Company Information

8.2.2 Incyte Business Overview

8.2.3 Incyte Tyrosine Kinase JAK Inhibitors Sales, Value and Gross Margin
(2019-2024)

8.2.4 Incyte Tyrosine Kinase JAK Inhibitors Product Portfolio

8.2.5 Incyte Recent Developments

8.3 Novartis

8.3.1 Novartis Company Information

8.3.2 Novartis Business Overview

8.3.3 Novartis Tyrosine Kinase JAK Inhibitors Sales, Value and Gross Margin
(2019-2024)

8.3.4 Novartis Tyrosine Kinase JAK Inhibitors Product Portfolio

8.3.5 Novartis Recent Developments

8.4 Eli Lilly

8.4.1 Eli Lilly Company Information

8.4.2 Eli Lilly Business Overview

8.4.3 Eli Lilly Tyrosine Kinase JAK Inhibitors Sales, Value and Gross Margin
(2019-2024)

8.4.4 Eli Lilly Tyrosine Kinase JAK Inhibitors Product Portfolio

8.4.5 Eli Lilly Recent Developments

8.5 Gilead

8.5.1 Gilead Company Information

8.5.2 Gilead Business Overview

8.5.3 Gilead Tyrosine Kinase JAK Inhibitors Sales, Value and Gross Margin
(2019-2024)

8.5.4 Gilead Tyrosine Kinase JAK Inhibitors Product Portfolio

8.5.5 Gilead Recent Developments

8.6 Sanofi

8.6.1 Sanofi Company Information

8.6.2 Sanofi Business Overview

8.6.3 Sanofi Tyrosine Kinase JAK Inhibitors Sales, Value and Gross Margin

(2019-2024)

8.6.4 Sanofi Tyrosine Kinase JAK Inhibitors Product Portfolio

8.6.5 Sanofi Recent Developments

8.7 Galapagos

8.7.1 Galapagos Company Information

8.7.2 Galapagos Business Overview

8.7.3 Galapagos Tyrosine Kinase JAK Inhibitors Sales, Value and Gross Margin

(2019-2024)

8.7.4 Galapagos Tyrosine Kinase JAK Inhibitors Product Portfolio

8.7.5 Galapagos Recent Developments

8.8 AbbVie

8.8.1 AbbVie Company Information

8.8.2 AbbVie Business Overview

8.8.3 AbbVie Tyrosine Kinase JAK Inhibitors Sales, Value and Gross Margin

(2019-2024)

8.8.4 AbbVie Tyrosine Kinase JAK Inhibitors Product Portfolio

8.8.5 AbbVie Recent Developments

8.9 Vertex

8.9.1 Vertex Company Information

8.9.2 Vertex Business Overview

8.9.3 Vertex Tyrosine Kinase JAK Inhibitors Sales, Value and Gross Margin

(2019-2024)

8.9.4 Vertex Tyrosine Kinase JAK Inhibitors Product Portfolio

8.9.5 Vertex Recent Developments

8.10 Teva

8.10.1 Teva Company Information

8.10.2 Teva Business Overview

8.10.3 Teva Tyrosine Kinase JAK Inhibitors Sales, Value and Gross Margin

(2019-2024)

8.10.4 Teva Tyrosine Kinase JAK Inhibitors Product Portfolio

8.10.5 Teva Recent Developments

8.11 Astellas Pharma

8.11.1 Astellas Pharma Company Information

8.11.2 Astellas Pharma Business Overview

8.11.3 Astellas Pharma Tyrosine Kinase JAK Inhibitors Sales, Value and Gross Margin

(2019-2024)

8.11.4 Astellas Pharma Tyrosine Kinase JAK Inhibitors Product Portfolio

8.11.5 Astellas Pharma Recent Developments

8.12 Celgene

- 8.12.1 Celgene Comapny Information
- 8.12.2 Celgene Business Overview
- 8.12.3 Celgene Tyrosine Kinase JAK Inhibitors Sales, Value and Gross Margin (2019-2024)
- 8.12.4 Celgene Tyrosine Kinase JAK Inhibitors Product Portfolio
- 8.12.5 Celgene Recent Developments
- 8.13 CTI BioPharma
 - 8.13.1 CTI BioPharma Comapny Information
 - 8.13.2 CTI BioPharma Business Overview
 - 8.13.3 CTI BioPharma Tyrosine Kinase JAK Inhibitors Sales, Value and Gross Margin (2019-2024)
 - 8.13.4 CTI BioPharma Tyrosine Kinase JAK Inhibitors Product Portfolio
 - 8.13.5 CTI BioPharma Recent Developments

9 VALUE CHAIN AND SALES CHANNELS ANALYSIS

- 9.1 Tyrosine Kinase JAK Inhibitors Value Chain Analysis
 - 9.1.1 Tyrosine Kinase JAK Inhibitors Key Raw Materials
 - 9.1.2 Raw Materials Key Suppliers
 - 9.1.3 Manufacturing Cost Structure
 - 9.1.4 Tyrosine Kinase JAK Inhibitors Sales Mode & Process
- 9.2 Tyrosine Kinase JAK Inhibitors Sales Channels Analysis
 - 9.2.1 Direct Comparison with Distribution Share
 - 9.2.2 Tyrosine Kinase JAK Inhibitors Distributors
 - 9.2.3 Tyrosine Kinase JAK Inhibitors Customers

10 CONCLUDING INSIGHTS

11 APPENDIX

- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
 - 11.5.1 Secondary Sources
 - 11.5.2 Primary Sources

List Of Tables

LIST OF TABLES

Table 1. Tyrosine Kinase JAK Inhibitors Industry Trends

Table 2. Tyrosine Kinase JAK Inhibitors Industry Drivers

Table 3. Tyrosine Kinase JAK Inhibitors Industry Opportunities and Challenges

Table 4. Tyrosine Kinase JAK Inhibitors Industry Restraints

Table 5. Global Tyrosine Kinase JAK Inhibitors Revenue by Company (US\$ Million) & (2019-2024)

Table 6. Global Tyrosine Kinase JAK Inhibitors Revenue Share by Company (2019-2024)

Table 7. Global Tyrosine Kinase JAK Inhibitors Sales Volume by Company (K Units) & (2019-2024)

Table 8. Global Tyrosine Kinase JAK Inhibitors Sales Volume Share by Company (2019-2024)

Table 9. Global Tyrosine Kinase JAK Inhibitors Average Price (USD/Unit) of Company (2019-2024)

Table 10. Global Tyrosine Kinase JAK Inhibitors Company Ranking, 2022 VS 2023 VS 2024 & (US\$ Million)

Table 11. Global Tyrosine Kinase JAK Inhibitors Key Company Manufacturing Base & Headquarters

Table 12. Global Tyrosine Kinase JAK Inhibitors Company, Product Type & Application

Table 13. Global Tyrosine Kinase JAK Inhibitors Company Commercialization Time

Table 14. Global Company Market Concentration Ratio (CR5 and HHI)

Table 15. Global Tyrosine Kinase JAK Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)

Table 16. Mergers & Acquisitions, Expansion

Table 17. Major Companies of Tofacitinib

Table 18. Major Companies of Ruxolitinib

Table 19. Major Companies of Baricitinib

Table 20. Global Tyrosine Kinase JAK Inhibitors Sales Volume by Type 2019 VS 2023 VS 2030 (K Units)

Table 21. Global Tyrosine Kinase JAK Inhibitors Sales Volume by Type (2019-2024) & (K Units)

Table 22. Global Tyrosine Kinase JAK Inhibitors Sales Volume by Type (2025-2030) & (K Units)

Table 23. Global Tyrosine Kinase JAK Inhibitors Sales Volume Share by Type (2019-2024)

Table 24. Global Tyrosine Kinase JAK Inhibitors Sales Volume Share by Type (2025-2030)

Table 25. Global Tyrosine Kinase JAK Inhibitors Sales Value by Type 2019 VS 2023 VS 2030 (US\$ Million)

Table 26. Global Tyrosine Kinase JAK Inhibitors Sales Value by Type (2019-2024) & (US\$ Million)

Table 27. Global Tyrosine Kinase JAK Inhibitors Sales Value by Type (2025-2030) & (US\$ Million)

Table 28. Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type (2019-2024)

Table 29. Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type (2025-2030)

Table 30. Major Companies of Rheumatoid Arthritis (RA)

Table 31. Major Companies of Polycythemia Vera (PCV)

Table 32. Major Companies of Myelofibrosis (MF)

Table 33. Major Companies of Others

Table 34. Global Tyrosine Kinase JAK Inhibitors Sales Volume by Application 2019 VS 2023 VS 2030 (K Units)

Table 35. Global Tyrosine Kinase JAK Inhibitors Sales Volume by Application (2019-2024) & (K Units)

Table 36. Global Tyrosine Kinase JAK Inhibitors Sales Volume by Application (2025-2030) & (K Units)

Table 37. Global Tyrosine Kinase JAK Inhibitors Sales Volume Share by Application (2019-2024)

Table 38. Global Tyrosine Kinase JAK Inhibitors Sales Volume Share by Application (2025-2030)

Table 39. Global Tyrosine Kinase JAK Inhibitors Sales Value by Application 2019 VS 2023 VS 2030 (US\$ Million)

Table 40. Global Tyrosine Kinase JAK Inhibitors Sales Value by Application (2019-2024) & (US\$ Million)

Table 41. Global Tyrosine Kinase JAK Inhibitors Sales Value by Application (2025-2030) & (US\$ Million)

Table 42. Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application (2019-2024)

Table 43. Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application (2025-2030)

Table 44. Global Tyrosine Kinase JAK Inhibitors Sales by Region: 2019 VS 2023 VS 2030 (K Units)

Table 45. Global Tyrosine Kinase JAK Inhibitors Sales by Region (2019-2024) & (K

Units)

Table 46. Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Region (2019-2024)

Table 47. Global Tyrosine Kinase JAK Inhibitors Sales by Region (2025-2030) & (K Units)

Table 48. Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Region (2025-2030)

Table 49. Global Tyrosine Kinase JAK Inhibitors Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US\$ Million)

Table 50. Global Tyrosine Kinase JAK Inhibitors Sales Value by Region (2019-2024) & (US\$ Million)

Table 51. Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Region (2019-2024)

Table 52. Global Tyrosine Kinase JAK Inhibitors Sales Value by Region (2025-2030) & (US\$ Million)

Table 53. Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Region (2025-2030)

Table 54. Global Tyrosine Kinase JAK Inhibitors Market Average Price (USD/Unit) by Region (2019-2024)

Table 55. Global Tyrosine Kinase JAK Inhibitors Market Average Price (USD/Unit) by Region (2025-2030)

Table 56. Global Tyrosine Kinase JAK Inhibitors Sales by Country: 2019 VS 2023 VS 2030 (K Units)

Table 57. Global Tyrosine Kinase JAK Inhibitors Sales Value by Country: 2019 VS 2023 VS 2030 (US\$ Million)

Table 58. Global Tyrosine Kinase JAK Inhibitors Sales by Country (2019-2024) & (K Units)

Table 59. Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Country (2019-2024)

Table 60. Global Tyrosine Kinase JAK Inhibitors Sales by Country (2025-2030) & (K Units)

Table 61. Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Country (2025-2030)

Table 62. Global Tyrosine Kinase JAK Inhibitors Sales Value by Country (2019-2024) & (US\$ Million)

Table 63. Global Tyrosine Kinase JAK Inhibitors Sales Value Market Share by Country (2019-2024)

Table 64. Global Tyrosine Kinase JAK Inhibitors Sales Value by Country (2025-2030) & (US\$ Million)

Table 65. Global Tyrosine Kinase JAK Inhibitors Sales Value Market Share by Country (2025-2030)

Table 66. Pfizer Company Information

Table 67. Pfizer Business Overview

Table 68. Pfizer Tyrosine Kinase JAK Inhibitors Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 69. Pfizer Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 70. Pfizer Recent Development

Table 71. Incyte Company Information

Table 72. Incyte Business Overview

Table 73. Incyte Tyrosine Kinase JAK Inhibitors Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 74. Incyte Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 75. Incyte Recent Development

Table 76. Novartis Company Information

Table 77. Novartis Business Overview

Table 78. Novartis Tyrosine Kinase JAK Inhibitors Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 79. Novartis Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 80. Novartis Recent Development

Table 81. Eli Lilly Company Information

Table 82. Eli Lilly Business Overview

Table 83. Eli Lilly Tyrosine Kinase JAK Inhibitors Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 84. Eli Lilly Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 85. Eli Lilly Recent Development

Table 86. Gilead Company Information

Table 87. Gilead Business Overview

Table 88. Gilead Tyrosine Kinase JAK Inhibitors Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 89. Gilead Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 90. Gilead Recent Development

Table 91. Sanofi Company Information

Table 92. Sanofi Business Overview

Table 93. Sanofi Tyrosine Kinase JAK Inhibitors Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 94. Sanofi Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 95. Sanofi Recent Development

Table 96. Galapagos Company Information

Table 97. Galapagos Business Overview

Table 98. Galapagos Tyrosine Kinase JAK Inhibitors Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 99. Galapagos Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 100. Galapagos Recent Development

Table 101. AbbVie Company Information

Table 102. AbbVie Business Overview

Table 103. AbbVie Tyrosine Kinase JAK Inhibitors Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 104. AbbVie Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 105. AbbVie Recent Development

Table 106. Vertex Company Information

Table 107. Vertex Business Overview

Table 108. Vertex Tyrosine Kinase JAK Inhibitors Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 109. Vertex Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 110. Vertex Recent Development

Table 111. Teva Company Information

Table 112. Teva Business Overview

Table 113. Teva Tyrosine Kinase JAK Inhibitors Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 114. Teva Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 115. Teva Recent Development

Table 116. Astellas Pharma Company Information

Table 117. Astellas Pharma Business Overview

Table 118. Astellas Pharma Tyrosine Kinase JAK Inhibitors Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 119. Astellas Pharma Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 120. Astellas Pharma Recent Development

Table 121. Celgene Company Information

Table 122. Celgene Business Overview

Table 123. Celgene Tyrosine Kinase JAK Inhibitors Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 124. Celgene Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 125. Celgene Recent Development

Table 126. CTI BioPharma Company Information

Table 127. CTI BioPharma Business Overview

Table 128. CTI BioPharma Tyrosine Kinase JAK Inhibitors Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 129. CTI BioPharma Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 130. CTI BioPharma Recent Development

Table 131. Key Raw Materials

Table 132. Raw Materials Key Suppliers

Table 133. Tyrosine Kinase JAK Inhibitors Distributors List

Table 134. Tyrosine Kinase JAK Inhibitors Customers List

Table 135. Research Programs/Design for This Report

Table 136. Authors List of This Report

Table 137. Secondary Sources

Table 138. Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. Tyrosine Kinase JAK Inhibitors Product Picture
- Figure 2. Global Tyrosine Kinase JAK Inhibitors Sales Value (US\$ Million), 2019 VS 2023 VS 2030
- Figure 3. Global Tyrosine Kinase JAK Inhibitors Sales Value (2019-2030) & (US\$ Million)
- Figure 4. Global Tyrosine Kinase JAK Inhibitors Sales (2019-2030) & (K Units)
- Figure 5. Global Tyrosine Kinase JAK Inhibitors Sales Average Price (USD/Unit) & (2019-2030)
- Figure 6. Global Tyrosine Kinase JAK Inhibitors Company Revenue Ranking in 2023 (US\$ Million)
- Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US\$ Million)
- Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
- Figure 9. Tofacitinib Picture
- Figure 10. Ruxolitinib Picture
- Figure 11. Baricitinib Picture
- Figure 12. Global Tyrosine Kinase JAK Inhibitors Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
- Figure 13. Global Tyrosine Kinase JAK Inhibitors Sales Volume Share 2019 VS 2023 VS 2030
- Figure 14. Global Tyrosine Kinase JAK Inhibitors Sales Volume Share by Type (2019-2030)
- Figure 15. Global Tyrosine Kinase JAK Inhibitors Sales Value by Type (2019 VS 2023 VS 2030) & (US\$ Million)
- Figure 16. Global Tyrosine Kinase JAK Inhibitors Sales Value Share 2019 VS 2023 VS 2030
- Figure 17. Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Type (2019-2030)
- Figure 18. Rheumatoid Arthritis (RA) Picture
- Figure 19. Polycythemia Vera (PCV) Picture
- Figure 20. Myelofibrosis (MF) Picture
- Figure 21. Others Picture
- Figure 22. Global Tyrosine Kinase JAK Inhibitors Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
- Figure 23. Global Tyrosine Kinase JAK Inhibitors Sales Volume Share 2019 VS 2023

VS 2030

Figure 24. Global Tyrosine Kinase JAK Inhibitors Sales Volume Share by Application (2019-2030)

Figure 25. Global Tyrosine Kinase JAK Inhibitors Sales Value by Application (2019 VS 2023 VS 2030) & (US\$ Million)

Figure 26. Global Tyrosine Kinase JAK Inhibitors Sales Value Share 2019 VS 2023 VS 2030

Figure 27. Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Application (2019-2030)

Figure 28. Global Tyrosine Kinase JAK Inhibitors Sales by Region: 2019 VS 2023 VS 2030 (K Units)

Figure 29. Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Region: 2019 VS 2023 VS 2030

Figure 30. Global Tyrosine Kinase JAK Inhibitors Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US\$ Million)

Figure 31. Global Tyrosine Kinase JAK Inhibitors Sales Value Share by Region: 2019 VS 2023 VS 2030

Figure 32. North America Tyrosine Kinase JAK Inhibitors Sales Value (2019-2030) & (US\$ Million)

Figure 33. North America Tyrosine Kinase JAK Inhibitors Sales Value Share by Country (%), 2023 VS 2030

Figure 34. Europe Tyrosine Kinase JAK Inhibitors Sales Value (2019-2030) & (US\$ Million)

Figure 35. Europe Tyrosine Kinase JAK Inhibitors Sales Value Share by Country (%), 2023 VS 2030

Figure 36. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Value (2019-2030) & (US\$ Million)

Figure 37. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Value Share by Country (%), 2023 VS 2030

Figure 38. Latin America Tyrosine Kinase JAK Inhibitors Sales Value (2019-2030) & (US\$ Million)

Figure 39. Latin America Tyrosine Kinase JAK Inhibitors Sales Value Share by Country (%), 2023 VS 2030

Figure 40. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Value (2019-2030) & (US\$ Million)

Figure 41. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Value Share by Country (%), 2023 VS 2030

Figure 42. USA Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 43. USA Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 44. USA Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 45. Canada Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 46. Canada Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 47. Canada Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 48. Germany Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 49. Germany Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 50. Germany Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 51. France Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 52. France Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 53. France Tyrosine Kinase JAK Inhibitors Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 54. U.K. Tyrosine Kinase JAK Inhibitors Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 55. U.K. Tyrosine Kinase JAK Inhibitors Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 56. U

I would like to order

Product name: Global Tyrosine Kinase JAK Inhibitors Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030

Product link: <https://marketpublishers.com/r/G5C2415C9E99EN.html>

Price: US\$ 4,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5C2415C9E99EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

